The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

Movement Disorders

Volumn 26, Issue 7, 2011, Pages 1225-1233

  Koprich, James B ^a,b   Fox, Susan H ^c   Johnston, Tom H ^a,b   Goodman, Allan ^d   Le Bourdonnec, Bertrand ^d   Dolle, Roland E ^d   Dehaven, Robert N ^d   Dehaven Hudkins, Diane L ^d   Little, Patrick J ^d   Brotchie, Jonathan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Atuka Ltd   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d ADOLOR CORPORATION   (United States)

Author keywords

Dyskinesia; L DOPA; Mu opioid antagonist; Non human primate; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADL 5510; LEVODOPA; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREA; DOSE RESPONSE; DYSKINESIA; DYSTONIA; FEMALE; LONG TERM CARE; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MACACA FASCICULARIS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PARKINSONIAN DISORDERS; RECEPTORS, OPIOID, MU;

EID: 79959365207     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23631     Document Type: Article

References (48)

1. Fahn S. Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl. 2006: 1-15.
2. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007; 22: 2409-2417.
3. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008; 71: 474-480.
4. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000; 342: 1484-1491.
5. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006; 21: 1844-1850.
6. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005; 20: 190-199.
7. Edley SM, Hall L, Herkenham M, Pert CB. Evolution of striatal opiate receptors. Brain Res. 1982; 249: 184-188.
8. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001; 2: 577-588.
9. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord. 1990; 5: 100-108.
10. Hashimoto T, Morita H, Tada T, Maruyama T, Yamada Y, Ikeda S-I. Neuronal activity in the globus pallidus in chorea caused by striatal lacunar infarction. Ann Neurol. 2001; 50: 528-531.
11. Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res. 1985; 339: 346-350.
12. Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol. 1999; 46: 732-738.
13. Rascol O, Sabatini U, Brefel C, et al. Cortical motor overactivation in parkinsonian patients with L-dopa- induced peak-dose dyskinesia. Brain. 1998; 121: 527-533.
14. Robertson RG, Farmery SM, Sambrook MA, Crossman AR. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res. 1989; 476: 317-322.
15. Vitek JL, Chockkan V, Zhang J-Y, et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol. 1999; 46: 22-35.
16. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol. 1999; 155: 204-220.
17. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol. 2003; 183: 458-468.
18. Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol. 2004; 185: 36-46.
19. Aubert I, Guigoni C, Li Q, et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3, 4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry. 2007; 61: 836-844.
20. Johansson PA, Andersson M, Andersson KE, Cenci MA. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis. 2001; 8: 220-239.
21. Henry B, Fox SH, Crossman AR, Brotchie JM. μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol. 2001; 171: 139-146.
22. Brooks DJ, Piccini P, Turjanski N, Samuel M. Neuroimaging of dyskinesia. Ann Neurol. 2000; 47(4 Suppl 1): S154-S158; discussion S158-S159.
23. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol. 1997; 42: 720-726.
24. Fox S, Silverdale M, Kellett M, et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord. 2004; 19: 554- 560.
25. Manson AJ, Katzenschlager R, Hobart J, Lees AJ. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry. 2001; 70: 554-556.
26. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord. 1994; 9: 437-440.
27. Samadi P, Gregoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bedard PJ. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naive parkinsonian monkeys. Neuropharmacology. 2005; 49: 165-173.
28. Samadi P, Gregoire L, Rouillard C, Bedard PJ. Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys. Neurobiol Dis. 2005; 19: 266-272.
29. Samadi P, Gregoire L, Bedard PJ. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology. 2003; 45: 954-963.
30. Samadi P, Gregoire L, Bedard PJ. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol Dis. 2004; 16: 246-253.
31. Mehta A, Bot G, Reisine T, Chesselet M-F. Endomorphin-1: induction of motor behavior and lack of receptor desensitization. J Neurosci. 2001; 21: 4436-4442.
32. DeHaven-Hudkins DL, Burgos LC, Cassel JA, et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther. 1999; 289: 494-502.
33. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther. 2010; 333: 865-873.
34. Hill MP, Brotchie JM. Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum. Br J Pharmacol. 1999; 127: 275-283.
35. Rawls SM, McGinty JF. Kappa receptor activation attenuates L-trans-pyrrolidine-2, 4-dicarboxylic acid-evoked glutamate levels in the striatum. J Neurochem. 1998; 70: 626-634.
36. Rawls SM, McGinty JF, Terrian DM. Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. J Neurochem. 1999; 73: 1058-1065.
37. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999; 290: 1034-1040.
38. Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord. 2005; 20: 403-409.
39. Newman DD, Rajakumar N, Flumerfelt BA, Stoessl AJ. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. NeuroReport. 1997; 8: 669-672.
40. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007; 22: 1379- 1389.
41. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm. 2005; 112: 359-391.
42. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008; 23: 2177- 2185.
43. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord. 2010; 25: 927-931.
44. Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol. 2008; 65: 577-583.
45. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008; 70: 2233-2240.
46. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol. 1996; 39: 574-578.
47. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol. 2003; 3: 54-61.
48. van der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 2005; 19: 1140-1142.